Vifor Pharma AG Financials

Market Capitalization CHF10.84 Billion as of Dec. 1, 2022

Valuations Metrics as of Jan. 25, 2025

Trailing PE	73.84
Forward PE	39.19
Price to Sales TTM	CHF5.95
Price to Book MRQ	CHF3.09
Enterprise to Revenue	5.97
Enterprise to EBITDA	19.68

Financial Reports as of Dec. 31, 2021

Financials

Fiscal Year Ends	2021-12-31
Most Recent Quarter	2021-12-31
Profit Margin	7.97%
Operating Margin	20.83%
Return on Assets TTM	4.58%
Return on Equity TTM	6.65%

Income Statement

Revenue TTM	CHF1,812,099,968
Revenue per Share TTM	CHF27.94
Quarterly Revenue Growth	%
Gross Profit TTM	CHF1,140,300,000
EBITDA	CHF714,800,000
Net Income to Common TTM	CHF146,600,000
Diluted EPS TTM	CHF2.25
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	CHF993,600,000
Total Cash per Share MRQ	CHF15.31
Total Debt MRQ	CHF
Total Debt to Equity MRQ	14.80
Current Ratio MRQ	1.91
Book Value per Share MRQ	CHF53.78

Cash Flow

Operating Cash Flow TTM	CHF527,400,000
Levered Free Cash Flow TTM	CHF302,112,512

VIFN Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	64,891,300
Float Shares	960,392
Avg 10 Volume	9,393
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	98.23%
% Held by Institutions	1.37%

Stock Price Summary

Beta	1.04
Fifty Two Week Low	CHF157.75
Fifty Two Week High	CHF197.20
Fifty Two Week Change	0.03%
Day 50 MA	CHF171.90
Day 200 MA	CHF173.04

Dividends and Splits

Forward Annual Dividend Rate	CHF8.00
Forward Annual Dividend Yield	4.82%
Trailing Annual Dividend Rate	CHF2.00
Trailing Annual Dividend Yield	1.21%
Payout Ratio	88.89%
Dividend Date	2022-05-03
Ex Dividend Date	2022-04-29
Last Split Factor
Last Split Date	2017-05-22